Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.51 |
| ▸ | NQO1 | P15559 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8810178 | 0.83 | HSD17B3 (0.53) | MAOBKDM4EALDH1A1HSD17B10TP53 | |
| SCHEMBL8745806 | 0.83 | NQO1 (0.52) | MAOBKDM4EALDH1A1HSD17B10TP53 | |
| SCHEMBL8745785 | 0.83 | NQO1 (0.52) | MAOBKDM4EALDH1A1HSD17B10TP53 | |
| SCHEMBL27617272 | 0.82 | HSD17B3 (0.61) | MAOBKDM4EALDH1A1HSD17B10HSD17B3 | |
| SCHEMBL8809004 | 0.82 | ERAP1 (0.62) | MAOBKDM4EALDH1A1HSD17B10TP53 | |
| SCHEMBL2552672 | 0.81 | ALDH1A1 (0.52) | MAOBKDM4EALDH1A1HSD17B10TP53 | |
| SCHEMBL13517935 | 0.80 | KDM4E (0.54) | MAOBKDM4EALDH1A1HSD17B10TP53 | |
| SCHEMBL8807762 | 0.79 | KDM4E (0.70) | MAOBKDM4EALDH1A1HSD17B10TP53 | |
| SCHEMBL19068971 | 0.78 | NQO1 (0.50) | MAOBKDM4EALDH1A1HSD17B10TP53 | |
| SCHEMBL2555284 | 0.78 | NQO1 (0.50) | MAOBKDM4EALDH1A1HSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154967-B1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | JOHNSON MATTHEY PLC (GB) | 2020-07-29 | — | — | EP | disclosed |
| US-9957283-B1 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-05-01 | — | — | US | disclosed |
| US-9957283-B1 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-05-01 | — | — | US | disclosed |
| US-9957283-B1 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2018-05-01 | — | — | US | disclosed |
| US-20180099982-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | MACFARLAN SMITH LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-20180099982-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | MACFARLAN SMITH LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-20180099982-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | MACFARLAN SMITH LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-9790237-B2 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9790237-B2 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-10-17 | — | — | US | disclosed |
| US-9790237-B2 | Processes for making alkylated arylpiperazine and alkylated arylpiperidine compounds including novel intermediates | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-10-17 | — | — | US | disclosed |
| US-20150361099-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | MACFARLAN SMITH LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-20150361099-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | MACFARLAN SMITH LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| US-20150361099-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | MACFARLAN SMITH LIMITED (GB) | 2015-12-17 | — | — | US | disclosed |
| EP-0584091-B1 | BENZOPYRANONES, METHODS OF MANUFACTURE AND USE THEREOF | SCHWABE WILLMAR GMBH & CO (DE) | 1997-01-15 | — | — | EP | disclosed |
| US-5428038-A | Administering for preventing or treating N-methyl-D-aspartate induced convulsions | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 1995-06-27 | — | — | US | disclosed |
| EP-0584091-A1 | BENZOPYRANONES, METHODS OF MANUFACTURE AND USE THEREOF. | SCHWABE WILLMAR GMBH & CO (DE) | 1994-03-02 | — | — | EP | disclosed |
| WO-1992018493-A1 | BENZOPYRANONES, METHODS OF MANUFACTURE AND USE THEREOF | DR. WILLMAR SCHWABE GMBH & CO. (DE) | 1992-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099982-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | NR5A2, NR4A3, NR4A2 | MAOB 961/4885KDM4E 1337/4885ALDH1A1 1383/4885 |
| US-20150361099-A1 | PROCESSES FOR MAKING ALKYLATED ARYLPIPERAZINE AND ALKYLATED ARYLPIPERIDINE COMPOUNDS INCLUDING NOVEL INTERMEDIATES | NR5A2, NR4A3, NR4A2 | MAOB 961/4885KDM4E 1337/4885ALDH1A1 1383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.